Summer 2015
Formulary Update

Magellan Rx Management, USHL Pharmacy Benefits Manager (PBM), has issued a formulary update.  Please take a moment to review the details below; changes have been incorporated into the member portal at


Product Update Background:
The Magellan Pharmacy and Therapeutics Committee (P&T) and Value Assessment Committee (VAC) meet periodically to review the status of the formulary and make recommendations. As a result of these periodic reviews, the formulary may be modified. The attached update summarizes Magellan formulary and utilization management changes resulting from their most recent P&T and VAC meeting.

Product Update Communications Plan:
Members with a prescription for any drug moving to Tier 3 status, within two months of the effective date of this change, will receive a personalized letter from Magellan naming the drug and identifying formulary therapeutic alternatives (Tier 1 & Tier 2).

Talking Points:
The Magellan P&T and VAC committees make changes to the formulary to help ensure that plan members have access to quality, safe and cost-effective prescription benefits. Use of the formulary is intended to encourage manufacturer recommended and FDA approved utilization of prescription medications and, when appropriate, effective management of drug costs.



Contact your USHL General Agent for additional details-- 

click below for an agent contact directory. 



 VISIT OUR WEBSITE                                          FEEDBACK OR QUESTIONS?